EA032959B9 - Применение бремеланотида в терапии женской сексуальной дисфункции - Google Patents

Применение бремеланотида в терапии женской сексуальной дисфункции

Info

Publication number
EA032959B9
EA032959B9 EA201590760A EA201590760A EA032959B9 EA 032959 B9 EA032959 B9 EA 032959B9 EA 201590760 A EA201590760 A EA 201590760A EA 201590760 A EA201590760 A EA 201590760A EA 032959 B9 EA032959 B9 EA 032959B9
Authority
EA
Eurasian Patent Office
Prior art keywords
bremelanotide
sexual dysfunction
human patient
therapy
female sexual
Prior art date
Application number
EA201590760A
Other languages
English (en)
Other versions
EA201590760A1 (ru
EA032959B1 (ru
Inventor
Carl Spana
Robert Jordan
Jeffrey D Edelson
Original Assignee
Palatin Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50628268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA032959(B9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Palatin Technologies Inc filed Critical Palatin Technologies Inc
Publication of EA201590760A1 publication Critical patent/EA201590760A1/ru
Publication of EA032959B1 publication Critical patent/EA032959B1/ru
Publication of EA032959B9 publication Critical patent/EA032959B9/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Предложен способ лечения женской сексуальной дисфункции у пациентки, предполагающей сексуальную активность, при уменьшении или сведении к минимуму побочных эффектов, ассоциированных с введением бремеланотида, включающий введение пациентке путем подкожной инъекции композиции, содержащей бремеланотид или фармацевтически приемлемую соль бремеланотида в количестве, достаточном для получения пиковой концентрации бремеланотида в плазме в течение 60 мин после введения пациентке, составляющей от 60 до 120 нг/мл.
EA201590760A 2012-11-05 2013-11-05 Применение бремеланотида в терапии женской сексуальной дисфункции EA032959B9 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261722511P 2012-11-05 2012-11-05
US201361770535P 2013-02-28 2013-02-28
PCT/US2013/068386 WO2014071339A2 (en) 2012-11-05 2013-11-05 Uses of bremelanotide in therapy for female sexual dysfunction

Publications (3)

Publication Number Publication Date
EA201590760A1 EA201590760A1 (ru) 2015-10-30
EA032959B1 EA032959B1 (ru) 2019-08-30
EA032959B9 true EA032959B9 (ru) 2019-11-27

Family

ID=50628268

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590760A EA032959B9 (ru) 2012-11-05 2013-11-05 Применение бремеланотида в терапии женской сексуальной дисфункции

Country Status (24)

Country Link
US (6) US9352013B2 (ru)
EP (1) EP2916856B2 (ru)
JP (1) JP6567971B2 (ru)
KR (1) KR102253526B1 (ru)
CN (2) CN117860866A (ru)
AU (1) AU2013337341B2 (ru)
BR (1) BR112015009936A8 (ru)
CA (1) CA2890081A1 (ru)
DK (1) DK2916856T4 (ru)
EA (1) EA032959B9 (ru)
ES (1) ES2701444T5 (ru)
FI (1) FI2916856T4 (ru)
GE (1) GEP20196947B (ru)
HK (1) HK1211227A1 (ru)
IL (1) IL238276B (ru)
MX (1) MX362610B (ru)
MY (1) MY179755A (ru)
NZ (1) NZ707246A (ru)
PH (1) PH12015500915A1 (ru)
PL (1) PL2916856T5 (ru)
SG (1) SG11201502949QA (ru)
UA (1) UA118656C2 (ru)
WO (1) WO2014071339A2 (ru)
ZA (1) ZA201503128B (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590209B2 (en) * 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794489B2 (en) * 1999-06-29 2004-09-21 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US20050222014A1 (en) * 1999-06-29 2005-10-06 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
WO2009151714A2 (en) * 2008-03-24 2009-12-17 Palatin Technologies, Inc. Therapeutic for treatment of circulatory shock, ischemia, inflammatory disease and related conditions
US20110065652A1 (en) * 2008-06-09 2011-03-17 Palatin Technologies, Inc. Melanocortin Receptor-Specific Peptides for Treatment of Sexual Dysfunction

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
AU2001263766A1 (en) * 2000-05-31 2001-12-11 Novo-Nordisk A/S A disposable double pointed injection needle, and an insulin injection system comprising a disposable double pointed injection needle
EP1441750A4 (en) 2001-07-11 2006-10-18 Palatin Technologies Inc LINEAR AND CYCLIC PEPTIDES SPECIFIC TO THE MELANOCORTIN RECEPTOR
CN101484198A (zh) * 2004-12-09 2009-07-15 韦斯特制药服务公司 尾部装有固定针的注射器和具有该注射器的自动注射装置
WO2011060352A1 (en) * 2009-11-16 2011-05-19 Ipsen Pharma S.A.S. Pharmaceutical compositions of melanocortin receptor ligands
KR102071212B1 (ko) * 2010-04-21 2020-01-30 애브비 바이오테크놀로지 리미티드 치료제의 제어된 전달을 위한 착용형 자동 주사 디바이스

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794489B2 (en) * 1999-06-29 2004-09-21 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US20050222014A1 (en) * 1999-06-29 2005-10-06 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
WO2009151714A2 (en) * 2008-03-24 2009-12-17 Palatin Technologies, Inc. Therapeutic for treatment of circulatory shock, ischemia, inflammatory disease and related conditions
US20110065652A1 (en) * 2008-06-09 2011-03-17 Palatin Technologies, Inc. Melanocortin Receptor-Specific Peptides for Treatment of Sexual Dysfunction

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PALATIN TECHNOLOGIES, INC. "Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder", ClinicalTnals.gov (NCT01382719) March 20,2012; [retrieved 10 February 2014]. Retrieved from the Internet: URL:http://clinicaltrials.gov/archive/NCT01382719/2012_03_20; page 1, brief summary; page 1, primary outcome; page 1, secondary outcome; page 2, intervention *
PALATIN TECHNOLOGIES, INC. "Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration", PR Newswire. August 12, 2009; [retrieved 10 February 2014]. Retrieved from the Internet: URL:http://www.thefreelibrary.com/Palatin+Technologies+Inc.+Reports+Positive+Bremelanotide+Study%3B...-a0205613302; page 1 *
SAFARINEJAD, M.R. "Evaluation of the Safety and Efficacy of Bremelanotide, a Melanocortin Receptor Agonist, in Female Subjects with Arousal Disorder: A Double-Blind Placebo-Controlled, Fixed Dose, Randomized Study". International Society for Sexual Medicine. 2008, 5:887-897; page 891, table 2 *

Also Published As

Publication number Publication date
ES2701444T3 (es) 2019-02-22
EA201590760A1 (ru) 2015-10-30
PH12015500915B1 (en) 2015-06-29
WO2014071339A2 (en) 2014-05-08
US20210060120A1 (en) 2021-03-04
BR112015009936A2 (pt) 2017-07-11
GEP20196947B (en) 2019-02-11
AU2013337341B2 (en) 2018-02-22
DK2916856T4 (da) 2024-01-22
MY179755A (en) 2020-11-12
US10286034B2 (en) 2019-05-14
EP2916856A2 (en) 2015-09-16
IL238276B (en) 2020-04-30
US20140378392A1 (en) 2014-12-25
DK2916856T3 (en) 2019-01-14
NZ707246A (en) 2019-03-29
US20150231196A1 (en) 2015-08-20
PL2916856T5 (pl) 2024-01-29
US9700592B2 (en) 2017-07-11
EP2916856B1 (en) 2018-09-19
JP2016503406A (ja) 2016-02-04
KR20150081345A (ko) 2015-07-13
US20180085425A1 (en) 2018-03-29
MX2015005486A (es) 2015-11-13
FI2916856T4 (fi) 2024-01-15
IL238276A0 (en) 2015-06-30
ES2701444T5 (es) 2024-05-21
CN117860866A (zh) 2024-04-12
ZA201503128B (en) 2016-11-30
PH12015500915A1 (en) 2015-06-29
WO2014071339A3 (en) 2014-06-12
CN104755094A (zh) 2015-07-01
BR112015009936A8 (pt) 2019-09-17
UA118656C2 (uk) 2019-02-25
KR102253526B1 (ko) 2021-05-18
US20190216888A1 (en) 2019-07-18
MX362610B (es) 2019-01-28
CA2890081A1 (en) 2014-05-08
EA032959B1 (ru) 2019-08-30
JP6567971B2 (ja) 2019-08-28
EP2916856B2 (en) 2023-10-18
HK1211227A1 (en) 2016-05-20
SG11201502949QA (en) 2015-06-29
AU2013337341A1 (en) 2015-05-07
US20220362328A1 (en) 2022-11-17
EP2916856A4 (en) 2016-06-22
US9352013B2 (en) 2016-05-31
PL2916856T3 (pl) 2019-02-28

Similar Documents

Publication Publication Date Title
AU2016202421B2 (en) Method of treating neurological conditions with cardiac glycosides
MX362626B (es) Métodos para tratar pacientes pediátricos usando dexmedetomidina..
UA115139C2 (uk) Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
WO2012023623A3 (ja) ハンター症候群の治療剤
NZ714963A (en) Compositions and methods for treating anemia
TN2015000067A1 (en) Method for administering hypnotic/sedative agent
NZ595767A (en) Composition for the treatment of prostate cancer
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
MX365688B (es) Sistemas de administracion de farmaco y metodos para el tratamiento del cancer de vejiga que comprenden oxaliplatino.
NZ702730A (en) Treatment of motor and movement disorder side effects associated with parkinson’s disease treatments
MX2012007875A (es) Uso de derivados de 5-[[2, 3-dimetil-2h-indazol-6-il)-metilamino]- 2-pirimidil] amino]-2-metilbencensulfonamida en transtornos oculares.
MX2018013715A (es) Composiciones acuosas de capsaicinoides que comprenden un analgesico y un vehiculo acuoso, y uso de las mismas para el tratamiento del dolor.
MX367070B (es) Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata.
AU2017312811A8 (en) Liquid naloxone spray
MX2016006179A (es) Formulaciones de capsaicinoides basadas en agua y metodos de manufactura y uso.
MX369117B (es) Antagonistas del receptor ep4 para el tratamiento de cancer.
MX2013008715A (es) Uso de (s) -esmolol para controlar la irritacion venosa asociada con el tratamiento de un padecimiento cardiaco.
EA032959B1 (ru) Применение бремеланотида в терапии женской сексуальной дисфункции
RU2012114097A (ru) Терапевтический агент против хронической боли
UA79795U (ru) Способ лечения остеоартропатий у больных сахарным диабетом
UA92302C2 (ru) Лекарственное средство для терапии злокачественных опухолей и способ лечения злокачественных опухолей с его использованием
UA83813U (ru) Способ лечения нейросифилиса с мезенхимальными изменениями
UA70494U (ru) Способ лечения посттромбофлебитной болезни нижних конечностей
MX2012012712A (es) Composicion farmaceutica para uso en el tratamiento o prevencion de una o varias enfermedaes inflamatorias y/o enfermedades autoinmunitarias.
RU2012110137A (ru) Способ лечения инсулинорезистентности

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM